New Study Examines Possible Cardiovascular Risk Factors Associated With A Mid-Life Uterine Fibroid Diagnosis
Monday, October 16, 2023 3:52 PM CT
Highlights From the American Society For Reproductive Medicine’s 2023 Scientific Congress
New Orleans, LA – Research presented at the American Society for Reproductive Medicine’s (ASRM) Scientific Congress examines the relationship between uterine fibroids and cardiovascular risk factors when diagnosis comes mid-life.
Researchers with the Study of Women’s Health Across the Nation (SWAN) examined prospectively the associations of hypertension, antihypertensive treatment, and cardiovascular risk factors with incidence of fibroid diagnosis in midlife. Over the course of their multi-year study, researchers state that the results indicate associations between hypertension and risk of newly diagnosed fibroids, which if causal could elucidate fibroid etiology and suggest new non-hormonal strategies to prevent fibroids.
- O-183 Mitro et al “Hypertension, Cardiovascular Risk Factors, And Uterine Fibroid Diagnosis In Midlife: Study Of Women’s Health Across The Nation (SWAN)”
Steven L Young, MD PhD, President of the Society for Reproductive Endocrinology and Infertility stated, “This work assists us and our patients to better understand the full impact of uterine fibroids. It is well beyond just the reproductive system.”
To view these abstracts and more in full, please visit: https://www.fertstert.org/issue/S0015-0282(23)X0012-0For almost a century, the American Society for Reproductive Medicine (ASRM) has been the global leader in multidisciplinary reproductive medicine research, ethical practice, and education. ASRM impacts reproductive care and science worldwide by creating funding opportunities for advancing reproduction research and discovery, by providing evidence-based education and public health information, and by advocating for reproductive health care professionals and the patients they serve. With members in more than 100 countries, the Society is headquartered in Washington, DC, with additional operations in Birmingham, AL. www.asrm.org
For media inquiries regarding this press release contact:
Sean Tipton
ASRM Chief Advocacy and Policy Officer
E: stipton@asrm.org
J. Benjamin Younger Office of Public Affairs
726 7th St. SE
Washington, DC 20003
Tel: (202) 863-2494
Fertility in the News
Doctors Group Launches Ad Campaign for Ohio Issue 1
ASRM announced the launch of an ad campaign throughout Ohio urging voters to select “Yes on Issue 1” when they head to the polls on November 7.
Dr. Paula Amato Sworn In As President Of The American Society For Reproductive Medicine
New Vice President and Board Members Announced
New Data Shows The Association Between Air Pollution And Miscarriage Risk
Research presented at ASRM 2023 examines the association between ambient air pollution and miscarriage.
New Research Focuses On The Need For DEI In Reproductive Medicine
New research delves into the challenges faced by underrepresented populations in accessing reproductive healthcare.
Resources For You
Fibroids or Myomas or Leiomyomas
SART Fertility Experts - Fibroids and Fertility
Fibroids and their impact on fertility are discussed in this episode featuring Dr. Elizabeth Stewart, interviewed by host Dr. Brooke Rossi. Listen to the Episode
Treatment of uterine fibroids
Do all fibroids require treatment? Not usually, because most patients with fibroids do not have symptoms. View the fact sheet
Fibroids and Fertility
Uterine fibroids are benign (noncancerous) tumors of muscle tissue in the uterus. They are also called myomas or leiomyomas. View the Fact Sheet
What are fibroids?
Uterine fibroids (also called myomas or leiomyomas) are benign (noncancerous) tumors of muscle tissue found in the uterus. View the fact sheet
Fibroids or Myomas or Leiomyomas Infographics
ASRM has prepared infographics to illustrate the subject of Fibroids better. View the infographicsFind a Health Professional
